Skip to main content
SpringerLink
Log in

Inhibition of 1,4-butanediol metabolism in human liver in vitro

  • ORIGINAL ARTICLE
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

The conversion of 1,4-butanediol (1,4-BD) to gamma-hydroxybutyric acid (GHB), a drug of abuse, is most probably catalyzed by alcohol dehydrogenase, and potentially by aldehyde dehydrogenase. The purpose of this study was to investigate the degradation of 1,4-BD in cytosolic supernatant of human liver in vitro, and to verify involvement of the suggested enzymes by means of gas chromatography–mass spectrometry. The coingestion of 1,4-BD and ethanol (EtOH) might cause complex pharmacokinetic interactions in humans. Therefore, the effect of EtOH on 1,4-BD metabolism by human liver was examined in vitro. Additionally, the influence of acetaldehyde (AL), which might inhibit the second step of 1,4-BD degradation, was investigated. In case of a 1,4-BD intoxication, the alcohol dehydrogenase inhibitor fomepizole (4-methylpyrazole, FOM) has been discussed as an antidote preventing the formation of the central nervous system depressing GHB. Besides FOM, we tested pyrazole, disulfiram, and cimetidine as possible inhibitors of the formation of GHB from 1,4-BD catalyzed by human liver enzymes in vitro. The conversion of 1,4-BD to GHB was inhibited competitively by EtOH with an apparent K i of 0.56 mM. Therefore, the coingestion of 1,4-BD and EtOH might increase the concentrations and the effects of 1,4-BD itself. By contrast AL accelerated the formation of GHB. All antidotes showed the ability to inhibit the formation of GHB. In comparison FOM showed the highest inhibitory effectiveness. Furthermore, the results confirm strong involvement of ADH in 1,4-BD metabolism by human liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Bessman SP, McCabe RB (1972) 1,4-butanediol—substrate for rat-liver and horse liver alcohol dehydrogenases. Biochem Pharmacol 21(8):1135–1142

    Article  PubMed  CAS  Google Scholar 

  • Brent J (2009) Fomepizole for ethylene glycol and methanol poisoning. N Engl J Med 360(21):2216–2223

    Article  PubMed  CAS  Google Scholar 

  • Carai MAM, Colombo G, Reali R, Serra S, Mocci I, Castelli MP, Cignarella G, Gessa GL (2002) Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid. Eur J Pharmacol 441(3):157–163

    Article  PubMed  CAS  Google Scholar 

  • Carai MAM, Colombo G, Quang LS, Maher TJ, Gessa GL (2006) Resuscitative treatments on 1,4-butanediol mortality in mice. Ann Emerg Med 47(2):184–189. doi:10.1016/j.annemergmed.2005.10.011

    Article  PubMed  Google Scholar 

  • Couper FJ, Marinetti LJ (2002) Hydroxybutyrate(GHB)—effects on human performance and behavior. Forensic Sci Rev 14:102–121

    Google Scholar 

  • Dawidek-Pietryka K, Szczepaniak S, Dudka J, Mazur M (1998) In vitro studies of human alcohol dehydrogenase inhibition in the process of methanol and ethylene glycol oxidation. Arch Toxicol 72(9):604–607

    Article  PubMed  CAS  Google Scholar 

  • Dempsey DA, Wiegand TJ, Havel C, Benowitz NL, Haller C (2009) Butanediol (BD) conversion to gamma-hydroxybutyrate, (GHB), is markedly reduced by fomepizole (4-MP), an alcohol dehydrogenase blocker. Clin Toxicol 47(7):113

    Google Scholar 

  • Duer WC, Byers KL, Martin JV (2001) Application of a convenient extraction procedure to analyze gamma-hydroxybutyric acid in fatalities involving gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol. J Anal Toxicol 25(7):576–582

    PubMed  CAS  Google Scholar 

  • Eriksson CJP (1983) Human-blood acetaldehyde concentration during ethanol oxidation (update 1982). Pharmacol Biochem Behav 18:141–150

    Article  PubMed  CAS  Google Scholar 

  • Fung HL, Tsou PS, Bulitta JB, Tran DC, Page NA, Soda D, Fung SM (2008) Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability. AAPS J 10(1):56–69. doi:10.1208/s12248-007-9006-3

    Article  PubMed  CAS  Google Scholar 

  • Kintz P, Villain M, Pelissier AL, Cirimele V, Leonetti G (2005) Unusually high concentrations in a fatal GHB case. J Anal Toxicol 29(6):582–585

    PubMed  CAS  Google Scholar 

  • Lad PJ, Leffert HL (1983) rat-liver alcohol-dehydrogenase.1. purification and characterization. Anal Biochem 133(2):350–361

    Article  PubMed  CAS  Google Scholar 

  • Lenz D, Rothschild MA, Kroner L (2008) Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone. Ther Drug Monit 30(6):755–761

    Article  PubMed  Google Scholar 

  • Lora-Tamayo C, Tena T, Rodriguez A, Sancho JR, Molina E (2003) Intoxication due to 1,4-butanediol. Forensic SciInt 133(3):256–259

    Article  CAS  Google Scholar 

  • Megarbane B, Fompeydie D, Garnier R, Baud FJ (2002) Treatment of a 1,4-butanediol poisoning with fomepizole. J Toxicol Clin Toxicol 40(1):77–80

    Article  PubMed  Google Scholar 

  • Poldrugo F, Snead OC (1984) 1,4 butanediol, gamma-hydroxybutyric acid and ethanol—relationships and interactions. Neuropharmacology 23(1):109–113

    Article  PubMed  CAS  Google Scholar 

  • Poldrugo F, Snead OC (1986) 1,4 butanediol and ethanol compete for degradation in rat-brain and liver invitro. Alcohol 3(6):367–370

    Article  PubMed  CAS  Google Scholar 

  • Poldrugo F, Barker S, Basa M, Mallardi F, Snead OC (1985) Ethanol potentiates the toxic effects of 1,4-butanediol. Alcoholism 9(6):493–497

    PubMed  CAS  Google Scholar 

  • Quang LS, DeSai MC, Shannon MW, Woolf AD, Maher TJ (2004) 4-methylpyrazole decreases 1,4-butanediol toxicity by blocking its in vivo biotransformation to gamma-hydroxybutyric acid. In: Ali SF, Nabeshima T, Yanagita T (eds) Current status of drug dependence/abuse studies: cellular and molecular mechanisms of drugs of abuse and neurotoxicity, vol 1025. Annals of the New York Academy of Sciences. New York Acad Sciences, New York, pp 528–537. doi:10.1196/annals.1316.065

  • Reynier M (1969) Pyrazole inhibition and kinetic studies of ethanol and retinol oxidation catalyzed by rat liver alcohol dehydrogenase. Acta Chem Scand 23(4):1119–1129

    Article  PubMed  CAS  Google Scholar 

  • Shen ML, Lipsky JJ, Naylor S (2000) Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 60(7):947–953

    Article  PubMed  CAS  Google Scholar 

  • Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150(1):76–85

    Article  PubMed  CAS  Google Scholar 

  • Snead OC, Gibson KM (2005) Drug therapy—gamma-hydroxybutyric acid. N Engl J Med 352(26):2721–2732

    Article  PubMed  CAS  Google Scholar 

  • Theorell H, Yonetani T (1969) On effects of some heterocyclic compounds on enzymic activity of liver alcohol dehydrogenase. Acta Chem Scand 23(1):255–260

    Article  PubMed  CAS  Google Scholar 

  • Tsukamoto S, Muto T, Nagoya T, Shimamura M, Saito M, Tainaka H (1989) Determinations of ethanol, acetaldehyde and acetate in blood and urine during alcohol oxidation in man. Alcohol Alcohol 24(2):101–108

    PubMed  CAS  Google Scholar 

  • Zorzano A, Herrera E (1989) Decreased in vivo rate of ethanol-metabolism in the suckling rat. Alcoholism 13(4):527–532

    PubMed  CAS  Google Scholar 

  • Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA (2001) Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 344(2):87–94

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors would like to thank the JÜRGEN MANCHOT STIFTUNG for financial support of this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Legal Medicine, University Hospital of Cologne, Melatengürtel 60-62, 50823, Cologne, Germany

    Daniel Lenz, Martin Jübner, Katja Bender, Annette Wintermeyer, Justus Beike, Markus A. Rothschild & Herbert Käferstein

Authors
  1. Daniel Lenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Jübner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katja Bender
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annette Wintermeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Justus Beike
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus A. Rothschild
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Herbert Käferstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Lenz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lenz, D., Jübner, M., Bender, K. et al. Inhibition of 1,4-butanediol metabolism in human liver in vitro. Naunyn-Schmiedeberg's Arch Pharmacol 383, 647–654 (2011). https://doi.org/10.1007/s00210-011-0627-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-011-0627-9

Keywords

Search

Navigation